Earnings Call Intelligence Subscribe
Home › Call Sheets › PFE › Q1'26
Call sheet · Q1'26

Pfizer (PFE)

Q1'26 earnings call · held May 5, 2026 · compared with the Q4'25 call · management-credibility review
11/12
Disclosure score
1 medium, 5 low flags
Financial quality
Bottom line
The sleeper story everyone will miss is that Vyndamax patent settlement just created $2B+ in annual cash flow through 2031 that wasn't in anyone's model - this transforms the post-2028 growth story and explains management's new confidence about high single-digit revenue CAGR starting 2029. Yes, they beat Q1 expectations, but the conservative guidance reaffirmation despite the beat suggests they're not confident about demand sustainability for their 22% growing launch portfolio. The binding constraint isn't demand or capacity - it's visibility into whether this quarter's launch portfolio acceleration is sustainable or just timing. Bourla's most revealing quote: 'absent COVID seasonality, we probably would be raising guidance' - translation, they're seeing strength but don't trust it yet. My view changes if launched/acquired products can sustain >20% growth for two more quarters and they start quantifying the AI productivity gains with specific R&D metrics.

The 30-second version

  • SLEEPER STORY: Vyndamax LOE settlement just created $2B+ in surprise cash flow annually through 2031
  • Launch portfolio accelerating but guidance conservative suggests visibility problems
  • R&D pivot to AI productivity creating cost structure advantage competitors can't match

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$17.6B (Q4 2025, -3% YoY)$14.5B (Q1 2026, +2% operational)+2% operational vs -3% prior quarter, beat expectations
Non-COVID Revenue~$13B (Q4 2025, +9% YoY)~$13.7B (Q1 2026, +7% operational)Growth decelerated from +9% to +7% but still solid
Launched/Acquired Products$10.2B (FY 2025, +14% operational)$3.1B (Q1 2026, +22% operational)Acceleration to +22% growth, strongest segment
Adjusted EPS$0.66 (Q4 2025)$0.75 (Q1 2026)+14% sequential, beat expectations
Adjusted Gross Margin~71% (Q4 2025)~76% (Q1 2026)+500bps expansion, back to mid-70s range
Operating Cash FlowNot disclosed Q4$2.6B (Q1 2026)Strong cash generation start to year
Adjusted Operating MarginNot specified Q438% (Q1 2026)Above pre-pandemic levels per management
COVID Product Revenue~$4.6B (Q4 2025, -40% YoY)Lower sequentialContinued decline as expected
R&D Investment$10.4B (FY 2025)$2.5B (Q1 2026)On pace for ~$10-11B annually with 20 pivotal starts
Leverage Ratio2.7x (end 2025)2.8x (Q1 2026)Slight increase, expect to stay current levels through LOE period

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full PFE Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.